In September, researchers at the European Society for Medical Oncology (ESMO) meeting in Berlin debated whether patients with head and neck cancer should receive cetuximab (Erbitux) instead of conventional chemotherapy, usually cisplatin, with radiation therapy. The case for cetuximab rests mainly on one phase III trial, published in 2006 in the New England Journal of Medicine . Led by James Bonner, M.D., at the University of Alabama at Birmingham, the trial showed a survival benefit for cetuximab with radiation, compared to radiation alone. On the other side of the debate, critics point to the limitations of this study, which did not directly compare cetuximab to cisplatin, and the lack of any further phase III studies. They conclude that the data are insufficient to warrant changing the standard of care. Arguments are stacked up on both sides of this debate. Cisplatin commonly has toxic effects during treatment that can continue for years, whereas cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has not so far been shown to have such problems. But scores of randomized trials have shown survival benefits when conventional chemotherapy is added to radiation treatments, robust results that are lacking for cetuximab.